GYPC and myeloid sarcoma: While the function of GPC5 remains poorly understood, particularly in MS, different GPC polymorphisms have been reported to increase the risk of lung cancer in non-smokers [72] while decreasing the risk of cancer in MS patients, with this reduced cancer risk stemming from the specific GPC gene [73].